Using the lymph nodal ratio to predict the risk of locoregional recurrence in lymph node-positive breast cancer patients treated with mastectomy without radiation therapy

[1]  San-Gang Wu,et al.  Using the lymph nodal ratio to predict the risk of locoregional recurrence in lymph node-positive breast cancer patients treated with mastectomy without radiation therapy , 2013, Radiation Oncology.

[2]  T. Kinoshita,et al.  Locoregional recurrence risk factors in breast cancer patients with positive axillary lymph nodes and the impact of postmastectomy radiotherapy , 2013, International Journal of Clinical Oncology.

[3]  Sung-Won Kim,et al.  The prognostic value of the nodal ratio in N1 breast cancer , 2011, Radiation oncology.

[4]  S. Ahn,et al.  Lymph node ratio and pN staging in patients with node-positive breast cancer: a report from the Korean breast cancer society , 2011, Breast Cancer Research and Treatment.

[5]  B. Haffty,et al.  Using Nodal Ratios to Predict Risk of Regional Recurrences in Patients Treated with Breast Conservation Therapy with 4 or More Positive Lymph Nodes , 2011, ISRN surgery.

[6]  M. M. M. Anees B. Chagpar MD,et al.  Lymph Node Ratio Should Be Considered for Incorporation into Staging for Breast Cancer , 2011, Annals of Surgical Oncology.

[7]  J. Olson,et al.  Improved staging in node-positive breast cancer patients using lymph node ratio: results in 1,788 patients with long-term follow-up. , 2010, Journal of the American College of Surgeons.

[8]  W. Woodward,et al.  Prognostic value of nodal ratios in node-positive breast cancer: a compiled update. , 2009, Future oncology.

[9]  P. Arnone,et al.  Rethinking TNM: A Breast Cancer Classification to Guide to Treatment and Facilitate Research , 2009, The breast journal.

[10]  G. Vlastos,et al.  Lymph node ratio as an alternative to pN staging in node-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Luini,et al.  Is avoiding post-mastectomy radiotherapy justified for patients with four or more involved axillary nodes and endocrine-responsive tumours? Lessons from a series in a single institution. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  J. Overgaard,et al.  Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. , 2007, Radiotherapy and Oncology.

[13]  John J Spinelli,et al.  Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. , 2005, Journal of the National Cancer Institute.

[14]  Yuting Zhang,et al.  Axillary Lymph Node Status, But Not Tumor Size, Predicts Locoregional Recurrence and Overall Survival After Mastectomy for Breast Cancer , 2003, Annals of surgery.

[15]  Donald L Weaver,et al.  Revision of the American Joint Committee on Cancer staging system for breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Love.  Meeting highlights: International Consensus Panel on the treatment of primary breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  B. Rasmussen,et al.  Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial , 1999, The Lancet.

[18]  K. Zedeler,et al.  Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. , 1997, The New England journal of medicine.

[19]  C. Redmond,et al.  The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. , 1981, Surgery, gynecology & obstetrics.